Cargando…

Development of a systemic lupus erythematosus cardiovascular risk equation

OBJECTIVE: Accelerated atherosclerosis remains the major cause of late death (after 5 years) in SLE. Yet, the ‘traditional’ cardiovascular risk equations (such as Framingham) consistently underestimate the risk. We sought to construct a data-driven formula for cardiovascular risk in SLE, based on da...

Descripción completa

Detalles Bibliográficos
Autores principales: Petri, Michelle A, Barr, Erik, Magder, Laurence S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827738/
https://www.ncbi.nlm.nih.gov/pubmed/31749976
http://dx.doi.org/10.1136/lupus-2019-000346
_version_ 1783465345538850816
author Petri, Michelle A
Barr, Erik
Magder, Laurence S
author_facet Petri, Michelle A
Barr, Erik
Magder, Laurence S
author_sort Petri, Michelle A
collection PubMed
description OBJECTIVE: Accelerated atherosclerosis remains the major cause of late death (after 5 years) in SLE. Yet, the ‘traditional’ cardiovascular risk equations (such as Framingham) consistently underestimate the risk. We sought to construct a data-driven formula for cardiovascular risk in SLE, based on data collected during the first year in a longitudinal cohort, for research purposes. METHODS: Two risk formulas were derived: one was for a broad set of cardiovascular outcomes (myocardial infarction, stroke, onset of angina, coronary procedures such as bypass or stent, claudication, peripheral artery disease or congestive heart failure); and the other for hard outcomes (myocardial infarction or stroke). Traditional and SLE-specific risk factors for cardiovascular disease were measured during the first year of cohort participation. Using Cox proportional hazards modelling, SLE formulas to calculate the 10-year risk of a subsequent cardiovascular event were derived and compared with the Framingham (for the broader outcome) and American College of Cardiology formulas (for the hard outcomes). RESULTS: SLE-related risk factors for each model included mean disease activity score (as measured by the SELENA revision of the SLE Disease Activity Index), low C3 and history of lupus anticoagulant. In those with SLE-related risk factors, the estimated 10-year risk based on our formula was substantially higher than the risk estimated based on the formulas for the general population. CONCLUSIONS: The excess cardiovascular risk among patients with SLE varies substantially depending on the SLE-related risk factors, age and traditional risk factors. Cardiovascular risk formulas based on individual data from patients with SLE may better estimate 10-year cardiovascular risk among patients with SLE than the Framingham or American College of Cardiology equations.
format Online
Article
Text
id pubmed-6827738
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-68277382019-11-20 Development of a systemic lupus erythematosus cardiovascular risk equation Petri, Michelle A Barr, Erik Magder, Laurence S Lupus Sci Med Epidemiology and Outcomes OBJECTIVE: Accelerated atherosclerosis remains the major cause of late death (after 5 years) in SLE. Yet, the ‘traditional’ cardiovascular risk equations (such as Framingham) consistently underestimate the risk. We sought to construct a data-driven formula for cardiovascular risk in SLE, based on data collected during the first year in a longitudinal cohort, for research purposes. METHODS: Two risk formulas were derived: one was for a broad set of cardiovascular outcomes (myocardial infarction, stroke, onset of angina, coronary procedures such as bypass or stent, claudication, peripheral artery disease or congestive heart failure); and the other for hard outcomes (myocardial infarction or stroke). Traditional and SLE-specific risk factors for cardiovascular disease were measured during the first year of cohort participation. Using Cox proportional hazards modelling, SLE formulas to calculate the 10-year risk of a subsequent cardiovascular event were derived and compared with the Framingham (for the broader outcome) and American College of Cardiology formulas (for the hard outcomes). RESULTS: SLE-related risk factors for each model included mean disease activity score (as measured by the SELENA revision of the SLE Disease Activity Index), low C3 and history of lupus anticoagulant. In those with SLE-related risk factors, the estimated 10-year risk based on our formula was substantially higher than the risk estimated based on the formulas for the general population. CONCLUSIONS: The excess cardiovascular risk among patients with SLE varies substantially depending on the SLE-related risk factors, age and traditional risk factors. Cardiovascular risk formulas based on individual data from patients with SLE may better estimate 10-year cardiovascular risk among patients with SLE than the Framingham or American College of Cardiology equations. BMJ Publishing Group 2019-10-10 /pmc/articles/PMC6827738/ /pubmed/31749976 http://dx.doi.org/10.1136/lupus-2019-000346 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Epidemiology and Outcomes
Petri, Michelle A
Barr, Erik
Magder, Laurence S
Development of a systemic lupus erythematosus cardiovascular risk equation
title Development of a systemic lupus erythematosus cardiovascular risk equation
title_full Development of a systemic lupus erythematosus cardiovascular risk equation
title_fullStr Development of a systemic lupus erythematosus cardiovascular risk equation
title_full_unstemmed Development of a systemic lupus erythematosus cardiovascular risk equation
title_short Development of a systemic lupus erythematosus cardiovascular risk equation
title_sort development of a systemic lupus erythematosus cardiovascular risk equation
topic Epidemiology and Outcomes
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827738/
https://www.ncbi.nlm.nih.gov/pubmed/31749976
http://dx.doi.org/10.1136/lupus-2019-000346
work_keys_str_mv AT petrimichellea developmentofasystemiclupuserythematosuscardiovascularriskequation
AT barrerik developmentofasystemiclupuserythematosuscardiovascularriskequation
AT magderlaurences developmentofasystemiclupuserythematosuscardiovascularriskequation